Singular Genomics Systems, Inc. (OMIC) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Singular Genomics Systems, Inc. (OMIC) Bundle
Designed for accuracy, our (OMIC) DCF Calculator enables you to evaluate Singular Genomics Systems, Inc. valuation using up-to-date financial data while providing comprehensive flexibility to modify all key parameters for improved projections.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | .8 | 2.9 | 3.6 | 4.5 | 5.7 | 7.1 | 8.9 |
Revenue Growth, % | 0 | 0 | 0 | 0 | 280.52 | 25 | 25 | 25 | 25 | 25 |
EBITDA | -12.0 | -26.4 | -60.5 | -84.1 | -86.5 | .7 | .9 | 1.1 | 1.4 | 1.8 |
EBITDA, % | 100 | 100 | 100 | -10991.37 | -2971.35 | 20 | 20 | 20 | 20 | 20 |
Depreciation | .4 | .6 | 1.1 | 6.0 | 7.2 | 3.6 | 4.5 | 5.7 | 7.1 | 8.9 |
Depreciation, % | 100 | 100 | 100 | 788.5 | 248.13 | 100 | 100 | 100 | 100 | 100 |
EBIT | -12.3 | -27.0 | -61.7 | -90.1 | -93.7 | .7 | .9 | 1.1 | 1.4 | 1.8 |
EBIT, % | 100 | 100 | 100 | -11779.87 | -3219.48 | 20 | 20 | 20 | 20 | 20 |
Total Cash | 46.2 | 26.9 | 339.2 | 244.6 | 173.9 | 3.6 | 4.5 | 5.7 | 7.1 | 8.9 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | 1.1 | 2.0 | 1.6 | 3.3 | 4.1 | 5.2 | 6.5 | 8.1 |
Account Receivables, % | 100 | 100 | 100 | 263.01 | 54.41 | 90.88 | 90.88 | 90.88 | 90.88 | 90.88 |
Inventories | .0 | .0 | 3.0 | 18.2 | 13.6 | 3.6 | 4.5 | 5.7 | 7.1 | 8.9 |
Inventories, % | 100 | 100 | 100 | 2381.83 | 466.23 | 100 | 100 | 100 | 100 | 100 |
Accounts Payable | .6 | .4 | 2.3 | 3.1 | 2.6 | 3.6 | 4.4 | 5.6 | 6.9 | 8.7 |
Accounts Payable, % | 100 | 100 | 100 | 405.1 | 88.87 | 97.77 | 97.77 | 97.77 | 97.77 | 97.77 |
Capital Expenditure | -.8 | -1.4 | -4.9 | -6.0 | -1.0 | -1.0 | -1.2 | -1.5 | -1.9 | -2.4 |
Capital Expenditure, % | 100 | 100 | 100 | -787.19 | -33.32 | -26.66 | -26.66 | -26.66 | -26.66 | -26.66 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -12.3 | -27.7 | -61.8 | -87.5 | -93.7 | .7 | .9 | 1.1 | 1.4 | 1.8 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -12.2 | -28.6 | -67.6 | -102.9 | -82.9 | 12.6 | 3.4 | 4.2 | 5.3 | 6.6 |
WACC, % | 7.22 | 7.22 | 7.22 | 7.14 | 7.22 | 7.2 | 7.2 | 7.2 | 7.2 | 7.2 |
PV UFCF | ||||||||||
SUM PV UFCF | 26.8 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 7 | |||||||||
Terminal Value | 130 | |||||||||
Present Terminal Value | 92 | |||||||||
Enterprise Value | 119 | |||||||||
Net Debt | 59 | |||||||||
Equity Value | 60 | |||||||||
Diluted Shares Outstanding, MM | 2 | |||||||||
Equity Value Per Share | 24.55 |
What You Will Get
- Real OMIC Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Singular Genomics Systems, Inc.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to [OMIC].
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Singular Genomics' fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for [OMIC].
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for Singular Genomics Systems, Inc.
Key Features
- Comprehensive Genomic Analysis Tools: Offers advanced tools for sequencing and data analysis tailored for genomic research.
- Customizable Bioinformatics Solutions: Pre-configured bioinformatics pipelines with options for user-defined parameters.
- Flexible Data Integration: Easily integrate various data types, including genomic, transcriptomic, and proteomic data.
- Built-In Analytical Metrics: Evaluate key performance indicators for genomic data interpretation.
- User-Friendly Dashboard: Interactive visualizations provide a clear overview of genomic insights and trends.
How It Works
- 1. Access the Template: Download and open the Excel file containing Singular Genomics Systems, Inc.'s preloaded data.
- 2. Modify Assumptions: Adjust key parameters such as growth rates, WACC, and capital expenditures.
- 3. Analyze Results in Real-Time: The DCF model automatically computes intrinsic value and NPV.
- 4. Explore Scenarios: Evaluate various forecasts to assess different valuation results.
- 5. Present with Assurance: Share professional valuation insights to bolster your decision-making process.
Why Choose This Calculator for Singular Genomics Systems, Inc. (OMIC)?
- Accurate Data: Utilize real financials from Singular Genomics for dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Ready-made calculations save you the effort of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: An intuitive design and clear step-by-step guidance make it accessible for all users.
Who Should Use This Product?
- Investors: Evaluate Singular Genomics' (OMIC) market position before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts for accuracy.
- Biotech Entrepreneurs: Understand the valuation strategies of leading genomic companies like Singular Genomics.
- Consultants: Provide comprehensive valuation analyses and reports for biotechnology clients.
- Students and Educators: Utilize current genomic industry data to learn and teach valuation practices.
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Singular Genomics Systems, Inc. (OMIC).
- Real-World Data: Singular Genomics’ historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Interactive charts and tables for clear, actionable results.